Answers are grounded in this paper and cite their sources.
BACKGROUND: The 6-min walk test (6MWT) is a useful tool to assess prognosis and functional impairment in various pulmonary diseases. AIMS: To evaluate functional capacity during various stages of pulmonary sarcoidosis and develop a scoring system clinical radiological physiological score (CRP) that can potentially be used to assess the functional status among patients with sarcoidosis. MATERIALS AND METHODS: We performed a retrospective study on 26 patients diagnosed with pulmonary sarcoidosis from 2001 to 2007. All patients completed the 6MWT. The parameters assessed during the test included spirometry, arterial blood gas, 6-min walk distance (6MWD), Borg dyspnea score, and initial and end oxygen saturation. RESULTS: Females covered a significantly shorter distance than males (343 m (223-389) vs. 416.5 m (352-500); P < 0.0001). In addition, females had a significantly lower SpO₂ at the end of the 6MWT than males (90.5 (61-99) vs. 96 (75-98); P < 0.03). The 6MWD was inversely correlated with the final Borg score (ρ = -0.603, P = 0.004) and the CRP score (ρ = -0.364, P = 0.047) and positively correlated with forced expiratory volume in 1 s (FEV₁) % ( ρ = 0.524, P = 0.006) and forced vital capacity (FVC) % (ρ = 0.407, P = 0.039). CONCLUSIONS: Female gender, FEV₁%, final Borg score, FVC%, CRP score, and SpO₂ at the end of the 6MWT are associated with reduced 6MWD. It appears that Saudi patients diagnosed with sarcoidosis have a markedly reduced walking distance compared with other races. The effect of race and ethnicity and the utility of the CRP score as a potential marker to assess functional status require further exploration.
No takes yet. Share an insight, caveat, or question.
Esam H. Alhamad (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: